Which checkpoint inhibitor improved therapy the most was dependent on which CAR T cell was used, as CAR T cells targeting EGFRvIII and IL13Rα2 both induced different checkpoint milieus in their respective tumor microenvironments. This evidence concerns the gene IL13RA2 and neoplasm.